Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 27, 2011 Dan Newman	How These Companies Earned a 22,000% Return A dollar invested in lobbying Congress can give a company fantastic returns.
The Motley Fool June 29, 2011 Morgan Housel	Come Home, Dear Cash Rooting for a repatriation holiday. Big businesses have tons of cash, yet most of it is parked overseas. Worse, they have every incentive to keep it there.
The Motley Fool June 30, 2011 Brian Orelli	Biotech Winners of a Repatriation Holiday Biotechs and dividend players will come out ahead.
IndustryWeek December 1, 2005	Taxation: Rush To Remit? Section 965, a potentially beneficial tax provision of the U.S. Internal Revenue Code, expires soon. Manufacturers need to determine now whether pursuing it makes financial sense.
The Motley Fool January 16, 2007 Chuck Saletta	All the Money in the World By investing in the foreign firms that benefit from America's outrageous tax laws, you can profit, too.
The Motley Fool November 25, 2011	A Brief History of Eli Lilly's Returns The good news is that, with shares now trading at around 10 times earnings, Eli Lilly looks reasonably valued, if not cheap.
The Motley Fool March 14, 2011 Brian Orelli	This Deal Is No Dog Eli Lilly picks up Johnson & Johnson's European animal-health business.
The Motley Fool January 18, 2012	What Johnson & Johnson Does With Its Cash Over the last five years, Johnson & Johnson shares returned 14%, which drops to -3% without dividends -- not a bad boost to top off otherwise lowly share performance.
The Motley Fool July 12, 2011 Todd Wenning	What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors.
The Motley Fool June 28, 2011 Eric Bleeker	Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales?
The Motley Fool January 28, 2010 Brian Orelli	The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.
BusinessWeek March 17, 2011 Coy & Drucker	Apple, Google May Profit on a Tax Holiday Those companies and others say they'll bring home billions in earnings -- but only if they get a big tax break.
CFO July 1, 2005 Don Durfee	Out of Exile The tax cut on foreign earnings only seems restrictive. But some companies remain wary.
The Motley Fool March 31, 2009 Brian Orelli	Pharma's Refreshing Bad News Schering-Plough and Eli Lilly both present data at scientific meetings over the weekend about drugs that failed their clinical trials, but it's not bad news.
BusinessWeek January 20, 2011 Cohn & Caminiti	The Multinational Tax Advantage A study of U.S.-based multinationals' effective tax rates shows the disadvantages of America's corporate tax system are not as great as some companies claim.
The Motley Fool November 20, 2009 Kris Eddy	Drug Companies Targeted, Again Is a review of drug prices by Congress something to worry about?
The Motley Fool May 26, 2010 Brian Orelli	Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues.
The Motley Fool December 10, 2009 Brian Orelli	A Tale of Two Lillys It was the best of times, it was the worst of times. Dickens could have been talking about Eli Lilly which has a tale of two cities all on its own.
The Motley Fool August 23, 2010 Jordan DiPietro	How Safe Are Eli Lilly's Dividends? Check out how Eli Lilly stacks up
The Motley Fool February 23, 2009 Brian Orelli	The DOJ v. Johnson & Johnson The U.S. Department of Justice is joining a lawsuit against the health care giant over the company's marketing of heart failure drug Natrecor.
The Motley Fool February 11, 2009 Brian Orelli	The FDA's Bipolar Decision Johnson & Johnson announces that the FDA has asked for more information before approving its application to market Risperdal Consta for frequently relapsing bipolar disorder.
BusinessWeek April 12, 2004 Howard Gleckman	Is Kerry's Jobs Proposal Jinxed? Rejiggering foreign taxes is politically savvy, but it won't help unemployment much
The Motley Fool August 27, 2008 Brian Orelli	Another FDA Setback for Johnson & Johnson The company has to wait for an approval of its extended-release schizophrenia drug. Investors, take note.
The Motley Fool December 17, 2009 Brian Orelli	This Acquisition Hears, Smells, and Tastes Soooo Good Johnson & Johnson picks up an ear, nose, and throat medical device maker.
Chemistry World August 9, 2012	Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials.
The Motley Fool April 21, 2010 Brian Orelli	Yawn! Get Back to Me Next Quarter, J&J There's more stagnant growth from the health-care giant.
The Motley Fool May 19, 2009 Brian Orelli	Flip-Flopping: Not Just for Politicians Anymore The FDA's change is good for companies.
The Motley Fool November 5, 2010 Brian Orelli	Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta.
The Motley Fool May 12, 2009 Brian Orelli	Another Reason to Hate Big Pharma's M&A As we get closer to Pfizer and Merck wrapping up their deals, it looks like a new group is voicing their displeasure: external partners.
The Motley Fool August 24, 2010 Brian Orelli	One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
The Motley Fool December 24, 2007 Rick Aristotle Munarriz	4 Stocks That Took a Hike These stocks recently raised their dividends: Pfizer... Eli Lilly... Moody's... Waste Management...
The Motley Fool October 12, 2004 Alyce Lomax	Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson?
The Motley Fool January 10, 2008 Brian Orelli	Good News for Lucky Men Eli Lilly's erectile dysfunction drug can now be taken daily.
The Motley Fool July 19, 2011 Brian Orelli	J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile.
The Motley Fool March 2, 2010 Brian Orelli	Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off.
The Motley Fool May 21, 2009 Brian Orelli	Not So Fast, Schering ... er, Merck ... er, Whoever You Are Merck got cute with its acquisition of Schering-Plough by setting up the merger so that Schering is technically merging with Merck and then changing its name to Merck. That seemingly schizophrenic move had a purpose.
The Motley Fool April 15, 2011 Brian Orelli	Dark Clouds Lift Over Pharma Dispute The case of who bought whom in the Merck -Schering-Plough deal has ended in a draw.
The Motley Fool April 13, 2009 Brian Orelli	Will These Drugs Get Past the FDA? Hopefully April won't bring showers of tears to these drugmakers: Eli Lilly... AstraZeneca... Bristol-Myers Squibb... Novo Nordisk... Johnson & Johnson...
The Motley Fool January 16, 2009 Brian Orelli	Lilly Pays Up. Big Deal. Lawsuits are just a fact of life when investing in drug companies, and pharmaceutical investors have to expect these kinds of legal defeats.
The Motley Fool September 2, 2008 Todd Wenning	Supercharge Your Income With These Stocks Dividend stocks offer the best option, but you need to start now.
The Motley Fool January 19, 2005 Chris Mallon	Bring Home the Billions A one-time corporate tax break could mean money in the bank for big multinationals. Investors ought to be cautious about buying companies based on strong 2005 earnings, and hopefully companies will clearly separate the "real" from the "one-time" in their reporting.
The Motley Fool October 19, 2010 Brian Orelli	Watch a 40% Decline Disappear The greatest thing going for Johnson & Johnson is its diversity in product offerings.
The Motley Fool December 31, 2008 Brian Orelli	An Imminent Drug Approval? Really? Lilly may finally hear about prasugrel.
The Motley Fool July 23, 2009 Brian Orelli	The Slowly Wilting Lilly Nothing can save this drug company.
The Motley Fool December 23, 2009 Brian Orelli	2009 Cheers and Jeers for Pharma Unfortunately, it was more of the latter.
The Motley Fool August 19, 2010 Brian Orelli	Buffett Is Buying J&J. Should You? It depends on your time horizon.
The Motley Fool November 24, 2010 Brian Orelli	A Manly FDA Approval Eli Lilly has something to be thankful for this week; the Food and Drug Administration approved Axiron, its testosterone replacement therapy.
The Motley Fool May 20, 2009 Brian Orelli	Joining to Treat, and Beat, Diabetes Medical-device maker Medtronic and drugmaker Eli Lilly are teaming up to co-promote the companies' diabetes products to doctors and patients.
The Motley Fool January 10, 2011 Dan Caplinger	Win With These Tax-Smart Stocks Congress has given you a lot more certainty on the tax front going forward, and by making the right investments, you can make the most of what lawmakers have given you with these stocks: Altria... Windstream... FirstEnergy... CenturyLink... Eli Lilly... Duke Energy...